New Data at ASCO GU Highlights Signatera’s Role in Bladder Preservation and Precision Medicine Why are precision medicine tools crucial for improving patient outcomes in genitourinary cancers? Natera, a global leader in cell-free DNA and precision medicine, is addressing this…
Promising Results for BCG-naïve NMIBC Patients Why are new treatment options for non-muscle invasive bladder cancer (NMIBC) crucial for patient outcomes? ImmunityBio a commercial-stage immunotherapy company, has completed enrollment in its Phase 2 clinical trial evaluating ANKTIVA® plus Bacillus Calmette-Guérin…
Hawks and Ressler Gertz Family Foundation Boost Prostate Cancer Research with $150,000 Donation Why is prostate cancer awareness and research crucial in the sports industry? The Atlanta Hawks Foundation, in partnership with the Ressler Gertz Family Foundation, has announced a…
AdvanCell Unveils Innovative Phase 2 Design for ADVC001 in Metastatic Prostate Cancer Why are new treatment options for metastatic prostate cancer crucial? AdvanCell, a clinical-stage radiopharmaceutical company, is addressing this urgent need with its innovative targeted alpha therapy, ADVC001. Based…
Preclinical Study Shows Targeted Degradation of MYC and KRAS Using Bionic Biologics Platform Why have traditional cancer treatments struggled to target the most aggressive forms of the disease? Grove Biopharma, a private biotechnology company based in Chicago, is addressing this…
Biotech Firm to Present at Psychedelic Therapeutics Conference in New Orleans Why are current treatments for neurodegenerative diseases often limited to symptom management? Five Discovery, a biotechnology company, is addressing this gap by developing small-molecule therapeutics to repair dysfunctional brain…
Expanding Access to Personalized Radiation Therapy for Prostate Cancer Patients Why do more than 20% of prostate cancer patients experience persistent urinary side effects after radiation therapy? MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, is…
Gossamer Bio Reports Mixed Results for Seralutinib in PAH, Demonstrates Strong Efficacy in High-Risk Subgroups Is the current landscape of pulmonary arterial hypertension (PAH) treatments failing to meet the needs of high-risk patients? Gossamer Bio, Inc. a biopharmaceutical company focused…
IDT Launches Advanced NGS Portfolio to Tackle Key Bottlenecks in Cancer Research As cancer research enters a new era defined by ultra-sensitive identification and rapidly expanding biomarker landscapes, Integrated DNA Technologies (IDT) is announcing a suite of next-generation sequencing (NGS)…
Global Healthcare Leader Organon Licenses Sebela Pharmaceuticals’ MIUDELLA for Diverse Reproductive Health Needs Why is the landscape of women’s reproductive health evolving so rapidly? Organon a global healthcare company with a mission to deliver impactful medicines and solutions for a…
Biotech Pioneer SylamoreBio Collaborates with Daiichi Sankyo to Tackle CNS Delivery Challenges How can biotech companies overcome the formidable barriers to delivering therapies to the central nervous system (CNS)? SylamoreBio, a biotechnology company dedicated to advanced therapeutic delivery, is addressing…
Gilead Sciences Seals $7.8 Billion Deal for Arcellx to Boost CAR T-Cell Therapy In the rapidly evolving landscape of cancer immunotherapies, where breakthroughs are crucial for patient outcomes, Gilead Sciences, Inc. has made a significant move. The biopharmaceutical giant has…